Strides have been made in the treatment of lung cancer in the lastdecade that warrant a
more optimistic outlook toward the disease. Therecent development of several new agents
with single-agent activity, including paclitaxel, docetaxel, vinorelbine, gemcitabine,
andirinotecan, is important, and those agents offer even greater potentialwhen they are used
in combination chemotherapy regimens or incombined-modality programs. The experience
to date with therapyresults with these agents in the treatment of lung cancer is reviewedand …